Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
暂无分享,去创建一个
B. Staels | J. Fruchart | C. Duval | Bart Staels | V. Kosykh | Thierry Claudel | Caroline Duval | Jean-Charles Fruchart | T. Claudel | Vladimir Kosykh | Inés Pineda Torra | I. Pineda Torra
[1] F. Gonzalez,et al. Antagonism of the Actions of Peroxisome Proliferator-activated Receptor-α by Bile Acids* , 2001, The Journal of Biological Chemistry.
[2] J. Chiang,et al. Regulation of cholesterol 7α-hydroxylase gene (CYP7A1) transcription by the liver orphan receptor (LXRα) , 2001 .
[3] D. Russell,et al. Nuclear Orphan Receptors Control Cholesterol Catabolism , 1999, Cell.
[4] A. Hamsten,et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients , 1996, The Lancet.
[5] K. von Bergmann,et al. Different effects of chenodeoxycholic acid and ursodeoxycholic acid on serum lipoprotein concentrations in patients with radiolucent gallstones. , 1982, Scandinavian journal of gastroenterology.
[6] M. Jaye,et al. PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway , 2001, Nature Medicine.
[7] J. Chiang,et al. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. , 2000, Journal of lipid research.
[8] J. Berger,et al. Differential Gene Regulation in Human Versus Rodent Hepatocytes by Peroxisome Proliferator-activated Receptor (PPAR) α , 2001, The Journal of Biological Chemistry.
[9] A. Soutar,et al. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.
[10] R. Hammer,et al. Cholesterol and Bile Acid Metabolism Are Impaired in Mice Lacking the Nuclear Oxysterol Receptor LXRα , 1998, Cell.
[11] B. Staels,et al. Peroxisome proliferator-activated receptors (PPARs): Nuclear receptors at the crossroads between lipid metabolism and inflammation , 2000, Inflammation Research.
[12] T. Werner,et al. MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data. , 1995, Nucleic acids research.
[13] Bruno Derudas,et al. Peroxisome Proliferator-activated Receptor α Activators Improve Insulin Sensitivity and Reduce Adiposity* , 2000, The Journal of Biological Chemistry.
[14] M. Makishima,et al. Human Bile Salt Export Pump Promoter Is Transactivated by the Farnesoid X Receptor/Bile Acid Receptor* , 2001, The Journal of Biological Chemistry.
[15] Y. Jamshidi,et al. Characterization of the Human PPAR Promoter : Identification of a Functional Nuclear Receptor Response Element , 2002 .
[16] M. Makishima,et al. Identification of a nuclear receptor for bile acids. , 1999, Science.
[17] A. Bonazzi,et al. Regulation of Cyclooxygenase-2 by Hypoxia and Peroxisome Proliferators in the Corneal Epithelium* , 2000, The Journal of Biological Chemistry.
[18] K. Einarsson,et al. Effects of cholestyramine and chenodeoxycholic acid on the metabolism of endogenous triglyceride in hyperlipoproteinemia. , 1978, Journal of lipid research.
[19] N. Abate,et al. Effects of different phenotypes of hyperlipoproteinemia and of treatment with fibric acid derivatives on the rates of cholesterol 7 alpha-hydroxylation in humans. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[20] Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001, The Lancet.
[21] K. Einarsson,et al. Effects of treatment with clofibrate, bezafibrate, and ciprofibrate on the metabolism of cholesterol in rat liver microsomes. , 1989, Journal of lipid research.
[22] D. Matthews,et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. , 1992, BMJ.
[23] J. Fruchart,et al. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition. , 1990, Metabolism: clinical and experimental.
[24] G. Cooney,et al. Peroxisome Proliferator—Activated Receptor (PPAR)-α Activation Lowers Muscle Lipids and Improves Insulin Sensitivity in High Fat—Fed Rats Comparison With PPAR-γ Activation , 2001 .
[25] T. Willson,et al. The PPARs: from orphan receptors to drug discovery. , 2000, Journal of medicinal chemistry.
[26] T. A. Kerr,et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.
[27] L. Agellon,et al. The Murine and Human Cholesterol 7α-Hydroxylase Gene Promoters Are Differentially Responsive to Regulation by Fatty Acids Mediated via Peroxisome Proliferator-activated Receptor α* , 2000, The Journal of Biological Chemistry.
[28] J. Auwerx,et al. Regulation of the peroxisome proliferator-activated receptor alpha gene by glucocorticoids. , 1994, The Journal of biological chemistry.
[29] T. Wilt,et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. , 1999, The New England journal of medicine.
[30] J. Auwerx,et al. Expression of the Peroxisome Proliferator-activated Receptor Gene Is Stimulated by Stress and Follows a Diurnal Rhythm (*) , 1996, The Journal of Biological Chemistry.
[31] Paul T Tarr,et al. Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor* , 2002, The Journal of Biological Chemistry.
[32] Jasmine Chen,et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. , 1999, Molecular cell.
[33] M. Hunt,et al. The Peroxisome Proliferator-activated Receptor α (PPARα) Regulates Bile Acid Biosynthesis* , 2000, The Journal of Biological Chemistry.
[34] L. Moore,et al. Identification of a chemical tool for the orphan nuclear receptor FXR. , 2000, Journal of medicinal chemistry.
[35] K. Einarsson,et al. Influence of bezafibrate on hepatic cholesterol metabolism in gallstone patients: Reduced activity of cholesterol 7α‐hydroxylase , 1995, Hepatology.
[36] H. Princen,et al. Regulation of Bile Acid Biosynthesis , 1997, Current Pharmaceutical Design.
[37] J Auwerx,et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. , 1998, Circulation.
[38] W. Wilkison,et al. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.
[39] T. Willson,et al. Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. , 2001, Molecular endocrinology.
[40] G. Steiner. Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study , 2001 .
[41] T. Willson,et al. Identification of a Bile Acid-responsive Element in the Human Ileal Bile Acid-binding Protein Gene , 1999, The Journal of Biological Chemistry.
[42] D. Mangelsdorf,et al. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. , 2000, Annual review of cell and developmental biology.
[43] M. Nieminen,et al. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. , 1997, Circulation.
[44] B. Angelin,et al. Gemfibrozil in familial combined hyperlipidaemia: effect of added low‐dose cholestyramine on plasma and biliary lipids , 1991, European journal of clinical investigation.
[45] G. Gil,et al. Alpha 1-fetoprotein transcription factor is required for the expression of sterol 12alpha -hydroxylase, the specific enzyme for cholic acid synthesis. Potential role in the bile acid-mediated regulation of gene transcription. , 2000, The Journal of biological chemistry.
[46] B. Angelin. Studies on the regulation of hepatic cholesterol metabolism in humans , 1995, European journal of clinical investigation.
[47] Masahiro Tohkin,et al. Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis , 2000, Cell.
[48] I. Björkhem,et al. Genes involved in initial steps of bile acid synthesis , 2001, Current opinion in lipidology.
[49] W. Wahli,et al. Peroxisome proliferator-activated receptors: nuclear control of metabolism. , 1999, Endocrine reviews.
[50] U. Francke,et al. Mutations in the bile acid biosynthetic enzyme sterol 27-hydroxylase underlie cerebrotendinous xanthomatosis. , 1991, The Journal of biological chemistry.
[51] N. Maeda,et al. Markedly Reduced Bile Acid Synthesis but Maintained Levels of Cholesterol and Vitamin D Metabolites in Mice with Disrupted Sterol 27-Hydroxylase Gene* , 1998, The Journal of Biological Chemistry.
[52] B Staels,et al. Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator–Activated Receptor-&agr;–Mediated Downregulation of Cholesterol 7&agr;-Hydroxylase and Sterol 27-Hydroxylase Expression , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[53] A. Anisfeld,et al. BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. , 2002, Journal of lipid research.
[54] Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. , 1995, The Journal of clinical investigation.
[55] A. Tedgui,et al. CLA-1/SR-BI is expressed in atherosclerotic lesion macrophages and regulated by activators of peroxisome proliferator-activated receptors. , 2000, Circulation.
[56] P. Dawson,et al. New insights into bile acid transport. , 1998, Current opinion in lipidology.
[57] P. Hylemon,et al. Regulation of sterol 12α-hydroxylase and cholic acid biosynthesis in the rat , 2000 .
[58] J. Dallongeville,et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. , 2002, The Journal of clinical investigation.
[59] W. Wahli,et al. Peroxisome proliferator–activated receptor α mediates the adaptive response to fasting , 1999 .
[60] J. Lehmann,et al. Bile acids: natural ligands for an orphan nuclear receptor. , 1999, Science.
[61] Jasmine Chen,et al. Identification of a nuclear receptor that is activated by farnesol metabolites , 1995, Cell.
[62] D. Moore,et al. The Farnesoid X-activated Receptor Mediates Bile Acid Activation of Phospholipid Transfer Protein Gene Expression* , 2000, The Journal of Biological Chemistry.
[63] K. Griffin,et al. A Carboxyl-terminal Extension of the Zinc Finger Domain Contributes to the Specificity and Polarity of Peroxisome Proliferator-activated Receptor DNA Binding* , 1998, The Journal of Biological Chemistry.
[64] A. Tall,et al. Targeted mutation of plasma phospholipid transfer protein gene markedly reduces high-density lipoprotein levels. , 1999, The Journal of clinical investigation.
[65] P. Edwards,et al. Identification of the DNA Binding Specificity and Potential Target Genes for the Farnesoid X-activated Receptor* , 2000, The Journal of Biological Chemistry.
[66] A. Soutar,et al. The effect of peroxisome-proliferator-activated receptor-alpha on the activity of the cholesterol 7 alpha-hydroxylase gene. , 2000, The Biochemical journal.
[67] B. Chatterjee,et al. Dehydroepiandrosterone Sulfotransferase Gene Induction by Bile Acid Activated Farnesoid X Receptor* , 2001, The Journal of Biological Chemistry.
[68] L. Moore,et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. , 2000, Molecular cell.
[69] J. Lehmann,et al. Activation of the orphan receptor RIP14 by retinoids. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[70] B Staels,et al. A truncated human peroxisome proliferator-activated receptor alpha splice variant with dominant negative activity. , 1999, Molecular endocrinology.